Thermo Fisher Scientific and NCI launch myeloMATCH trial to advance AML and MDS treatment

Pallavi Madhiraju- July 13, 2024 0

In a significant advancement in cancer treatment, Thermo Fisher Scientific Inc. (NYSE: TMO) has partnered with the National Cancer Institute (NCI), a component of the ... Read More

Immune-Onc Therapeutics gets FDA orphan drug status for IO-202 in CMML

Pallavi Madhiraju- February 22, 2024 0

Immune-Onc Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of innovative therapies in immunology and oncology, has achieved a significant milestone with the ... Read More

Kurome Therapeutics advances with FDA-approved IND for KME-0584 in AML and HR MDS clinical trial

Pallavi Madhiraju- February 17, 2024 0

In a significant development for cancer research, Kurome Therapeutics Inc. has announced the U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug ... Read More

Hemogenyx Pharmaceuticals receives FDA nod for HEMO-CAR-T AML treatment study

Pallavi Madhiraju- February 10, 2024 0

Hemogenyx Pharmaceuticals plc, a London-based biopharmaceutical company, has received approval from the U.S. Food and Drug Administration (FDA) to proceed with its Phase I clinical ... Read More

Invivoscribe, Complete Genomics to develop biomarker tests for oncology research

Pallavi Madhiraju- June 3, 2023 0

Invivoscribe and Complete Genomics have announced a partnership aimed at developing and commercializing biomarker tests on the latter’s next-generation sequencing (NGS) platforms. The collaboration, covering ... Read More

Rigel Pharmaceuticals gets Rezlidhia FDA approval for AML

Raghuram Kadari- December 6, 2022 0

Rigel Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for its Rezlidhia (olutasidenib) capsules for relapsed or refractory (R/R) acute myeloid ... Read More

Medac resubmits treosulfan NDA to FDA, says Medexus Pharmaceuticals

pallavi123- July 30, 2022 0

Medexus Pharmaceuticals said that its strategic partner medac has resubmitted the new drug application (NDA) for treosulfan with the US Food and Drug Administration (FDA). ... Read More

Curis doses first patient in CA-4948 phase 1 clinical trial in AML and MDS

pharmanewsdaily- July 7, 2020 0

CA-4948 phase 1 clinical trial : US biotech company Curis said that it has dosed the first patient with CA-4948 in a phase 1 clinical ... Read More

Gilead Sciences wraps up $4.9bn acquisition of Forty Seven

pharmanewsdaily- April 13, 2020 0

Gilead Sciences has completed its previously announced $4.9 billion acquisition of Forty Seven, a clinical-stage immuno-oncology company based in California. The immuno-oncology company has been ... Read More

Gilead Sciences to acquire immuno-oncology company Forty Seven for $4.9bn

pharmanewsdaily- March 3, 2020 0

Gilead Sciences acquisition of Forty Seven : US biotech company Gilead Sciences has signed an all-cash deal worth around $4.9 billion to acquire Forty Seven, ... Read More